Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2014 · 10-Q
Revenue$31.01M$31.01M−16.7% vs Q2 2013 Net Income-$2.66M-$2.66MN/M vs Q2 2013 EPS Diluted-$0.18-$0.18N/M vs Q2 2013 Gross Profit$5,193,000−24.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,825,000N/M Free Cash Flowderived-$2,171,000N/M Margins · derivedGross margin16.7%−1.6 pt vs Q2 2013
Operating margin-3.4%−1.2 pt vs Q2 2013
Net margin-8.6%−6.2 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end